Molecule
Allogeneic thymocyte-depleted thymus tissue is a prescription medicine indicated for immune reconstitution in pediatric patients with congenital athymia. It is available as implants for intramuscular use. MedsAcross supplies Allogeneic thymocyte-depleted thymus tissue for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
RETHYMIC ® is indicated for immune reconstitution in pediatric patients with congenital athymia. Limitations of Use: RETHYMIC is not indicated for the treatment of patients with severe combined immunodeficiency (SCID).
Source: US FDA prescribing information
RETHYMIC is intended to reconstitute immunity in patients who are athymic. The proposed mechanism of action involves the migration of recipient T cell progenitors from the bone marrow to the implanted RETHYMIC slices, where they develop into naïve immunocompetent recipient T cells. Evidence of thymic function can be observed with the development of naïve T cells in the peripheral blood, this is unlikely to be observed prior to 6-12 months after treatment with RETHYMIC.
Source: US FDA prescribing information
RETHYMIC is administered by a surgical procedure. The recommended dose range is 5,000 to 22,000 mm 2 of RETHYMIC/m 2 recipient body surface area (BSA). Immunosuppressive therapy is recommended for patients receiving RETHYMIC based on disease phenotype and PHA levels.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Immune reconstitution sufficient to protect from infection is unlikely to develop prior to 6 to 12 months after treatment with RETHYMIC. Given the immunocompromised condition of athymic patients, infection control measures should be followed until the development of thymic function can be established. Monitor and treat patients at risk for the development of graft versus host disease (GVHD). Monitor for the development of autoimmune disorders, including complete blood counts with differential, liver enzymes, serum creatinine, urinalysis, and thyroid function. Pre-existing renal impairment is a risk factor for death. Pre-existing cytomegalovirus infection may result in death prior to the development of thymic function. Monitor for the development of lymphoproliferative disorder (blood cancer). Transmission of infectious diseases may occur because RETHYMIC is derived from human tissue.
Source: US FDA prescribing information
The most common adverse reactions (incidence in at least 10% of patients) reported following administration of RETHYMIC were hypertension (high blood pressure), cytokine release syndrome, rash, hypomagnesemia (low magnesium), renal impairment / failure (decrease of kidney function), thrombocytopenia (low platelets), and graft versus host disease. The most common (>10%) adverse events related to RETHYMIC included: hypertension (high blood pressure, 19%), cytokine release syndrome (18%), rash (15%), hypomagnesemia (low magnesium, 16%), renal impairment / failure (decrease of kidney function, 12%), thrombocytopenia (low platelets, 12%), and graft versus host disease, (10%). or https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.
Source: US FDA prescribing information
No drug interaction studies have been conducted with RETHYMIC. If possible, prolonged use of immunosuppressive therapies, including high-dose corticosteroids, should be avoided.
Source: US FDA prescribing information
Store RETHYMIC at room temperature in the polycarbonate container in the insulated shipping box until ready for use. Do not refrigerate, freeze, agitate, or sterilize RETHYMIC.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Allogeneic thymocyte-depleted thymus tissue, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Rethymic 22000 mm implantIntramuscular | Sumitomo Pharma | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | Not recorded | — |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Allogeneic thymocyte-depleted thymus tissue and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Allogeneic thymocyte-depleted thymus tissue, including Rethymic.
No listed presentation of Allogeneic thymocyte-depleted thymus tissue is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.